GT 02329
Alternative Names: GT-02329Latest Information Update: 01 Mar 2023
At a glance
- Originator Gain Therapeutics
- Class Antiparkinsonians; Pharmacological chaperones; Small molecules
- Mechanism of Action Glucosylceramidase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gaucher's disease; Parkinson's disease